Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma

PHASE1RecruitingINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

December 31, 2024

Conditions

Solid Tumors or Lymphoma

Interventions

BIOLOGICAL

IBI363

a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.

Trial Locations (1)

RECRUITING

First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY